Press Releases PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.98 ^USD	+1.02%		-3.25%	-40.04%

May. 15	PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 10	NetScientific says PDS Biotech's Versamune meets endpoints	AN

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PDS Biotechnology: Q1 Earnings Snapshot	May. 15	AQ
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results	May. 15	AQ
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer	May. 09	AQ
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences	May. 09	AQ
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024	May. 07	AQ
PDS Biotechnology Announces Details of Virtual KOL Event	May. 06	AQ
PDS Biotechnology Announces Details of Virtual KOL Event	May. 03	AQ
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer	May. 02	AQ
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer	Apr. 24	AQ
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer	Apr. 23	AQ
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results	Mar. 28	AQ
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results	Mar. 27	AQ
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results	Mar. 20	AQ
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®	Mar. 13	AQ
PDS Biotechnology : Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune® - Form 8-K	Mar. 13	PU
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer	Jan. 22	AQ
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference	Jan. 16	AQ
PDS Biotechnology Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	Dec. 05	AQ
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Dec. 04	AQ
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer	Nov. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Press Releases

Filters